VK2735 for Weight Management Phase 2

NCT06068946 on ClinicalTrials.gov · last registry update 2025-02-12

Finished 27 February 2024, after enrolling 176 people. Primary outcome, as filed: Percent (relative) change from baseline to Week 13 in body weight. VK2735 is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.

Status: COMPLETED
Phase: P2
Drug: VK2735
Sponsor: Viking Therapeutics, Inc.
Sponsor type: Industry
Enrollment: 176
Started: 2023-08-31
Primary completion: 2024-02-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent (relative) change from baseline to Week 13 in body weight

Conditions studied

Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the VK2735 page for this molecule’s full trial and approval history.